Tissue-directed antibodies and methods of using the same
US-2024342260-A1 · Oct 17, 2024 · US
PD-1 antibodies and PD-L1 antibodies and uses thereof
US9637546B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9637546-B2 |
| Application number | US-201414282319-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2014 |
| Priority date | Feb 9, 2009 |
| Publication date | May 2, 2017 |
| Grant date | May 2, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A PD-1 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4122 or a derivative thereof having the same CDRs as the PD-1 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4122. 2. A method of blocking the activity of PD-1 in a cell comprising contacting said cell with a PD-1 antibody according to claim 1 , wherein said PD-1 antibody blocks the interaction of said PD-1 with PD-L1. 3. A method of blocking the activity of PD-1 in a cell comprising contacting said cell with a PD-1 antibody according to claim 1 , wherein said PD-1 antibody blocks the interaction of said PD-1 with PD-L2. 4. The method of claim 2 wherein said cell is in a human or animal subject. 5. The method of claim 3 wherein said cell is in a human or animal subject.
Assignees
Inventors
Classifications
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
- C07K16/2896Primary
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9637546B2 cover?
- The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
- Who is the assignee on this patent?
- Univ Aix Marseille, Inserm (Institut Nat De La Sante Et De La Rech Medicale), Inst Paoli Calmettes
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).